Preclinical and clinical studies demonstrate that programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) antibodies have promising anti-tumor activities in patients with cancer, including GC (2, 3). This evidence concerns the gene CD274 and gastric cancer.